Method of treatment with anti-inflammatory and analgesic compounds which are gi-, renal-, and platelet-sparing

Abstract

Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.

What is claimed is: 
     
         1 . A method of treatment of pain or inflammation in a patient with a history of peptic ulcer disease or at increased risk of gastrointestinal bleeding/ulceration/obstruction and in need of such treatment, comprising administering a therapeutically effective amount of methylglyoxal-bisguanylhydrazone (MGBG), wherein the therapeutically effective amount of MGBG does not inhibit cyclooxygenase and is not an opioid or a steroid, and is gastrointestinal-, platelet-, and renal-sparing. 
     
     
         2 . The method as recited in  claim 2 , wherein the compound is formulated for oral delivery. 
     
     
         3 . The method as recited in  claim 3 , wherein the compound is formulated for delayed-release oral delivery to the small bowel. 
     
     
         4 . The method as recited in  claim 1 , wherein non-steroidal anti-inflammatory drugs (NSAIDs) are not advisable or contraindicated in the patient. 
     
     
         5 . The method as recited in  claim 1 , wherein the patient has a bleeding or clotting disorder. 
     
     
         6 . The method as recited in  claim 1 , wherein the patient has an increased risk for bleeding. 
     
     
         7 . The method as recited in  claim 1 , wherein the patient has a gastrointestinal disorder. 
     
     
         8 . The method as recited in  claim 1 , wherein the patient has a renal disorder. 
     
     
         9 . The method as recited in  claim 1 , wherein the patient has a disorder in which sodium/fluid retention is undesirable. 
     
     
         10 . The method as recited in  claim 1 , wherein the patient is taking an anti-coagulant drug. 
     
     
         11 . The method as recited in  claim 1 , wherein the patient has a renal disease, congestive heart failure, or cirrhosis, or is volume-depleted or dehydrated. 
     
     
         12 . The method as recited in  claim 1 , wherein the patient has cirrhosis or thrombocytopenia. 
     
     
         13 . The method as recited in  claim 1 , wherein the patient is pre-operative for surgery. 
     
     
         14 . The method as recited in  claim 1 , wherein the patient has a history of peptic ulcer disease or at increased risk of gastrointestinal bleeding/ulceration/obstruction.